Crohn'
Conditions
Interventions
None listed
Sponsors
Janssen Pharma K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Men and women aged over 16 years. 2.Pstients newly given a CD diagnosis according to MHLW criteria on or after June 1,2016. 3.Each subject must sign an Informed Consent Form(ICF) indicating that subject understands the purpose of and procedures required for the study and are willing to participate in the study.(if the subject is minor, informed assent might be obtained from each study subject according to the regulation of institution/hospital and their legally acceptable representative must sign an ICF).
Exclusion criteria
Exclusion criteria: 1.Patients who have used a biological drug having an indication for auto-immune diseases before diagnosis of CD 2.Patients with unknown dates (month and year) of CD diagnosis. 3.Patients currently enrolled or expected to be enrolled in other registration trial(s) at the registry entry.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of proportion(%)of patients using each CD treatment after CD diagnosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Time to start using a biological drug from CD diagnosis 2.Duration of each CD treatment, Time to next CD treatment 3.Time to CD-related surgery from CD diagnosis 4.Change in HBI score in 4 years 5.Change in QOL indices (FACIT-Fatigue, short inflammatory bowel disease questionnaire[SIBDQ], and work productivity and activity impairment questionnaire: General Health[WPAI:GH])in 4 years. 6.Adverse events in each drug therapy for CD | — |
Countries
Japan
Contacts
Public ContactYutaro Kawagoe
EP-CRSU Co., Ltd Project Management Promotion Department
Outcome results
None listed